Tel Aviv-yafo, Israel
Tel Aviv-yafo, Israel

Time filter

Source Type

BOSTON, MA, May 15, 2017 (GLOBE NEWSWIRE) -- IMP Consulting, a leader in OMS implementation and compliance solutions for the asset management industry, today announced the release of CLEAR Recon as the latest addition to its growing compliance practice.  The CLEAR (Compliance Library Enhancement and Audit Review) suite of services enable compliance teams to identify and correct inaccurate, duplicate, and outdated rules in the trade OMS compliance rule library for buy-side investment management firms. The latest offering, CLEAR Recon, produces a set of on-demand reports highlighting missing rules, missing accounts or account groups, missing rule assignments, or variances in end-of-day compliance results. CLEAR Recon is a repeatable process that takes the human error component out of compliance reconciliation; reduces the risk of trade errors; and replaces a time-consuming manual process. It can be run at any point in the compliance lifecycle, from rule library analysis to implementation. “Many firms surprisingly rely on Excel spreadsheets for rule reconciliation. One mistake, or even a small typo, in the spreadsheet can have an enormous impact, such as costly trade errors or SEC scrutiny,” said Bryon Williston, Executive Vice President of IMP. “An automated tool, such as CLEAR Recon, takes the human error out of the process, and can deliver the break reports faster, and more accurately.” IMP Consulting, founded in 2004, initially developed CLEAR after observing that many firms were reaching a critical point where the manageability of the compliance rule library, and the process and controls around them, were failing. “CLEAR is backed by a team of compliance experts at IMP who understand the regulatory requirements governing the different investment vehicles, and can accurately translate them into code across all of the market-leading compliance systems,” said Williston. “These specialists work with compliance and IT teams to produce the required import, and properly map the files - saving days, or months of work for people.” The CLEAR suite of services also includes CLEAR 360 and CLEAR On-Demand. Visit http://www.impconsults.com/clear/ for more information. About IMP Consulting IMP Consulting is the industry leader in OMS implementation and compliance solutions for buy-side investment management firms and hedge funds. IMP also offers advisory services, system review and selection, and management of outsourced projects across the front, middle and back-office. Known for their deep subject matter expertise in Trade Order Management, Compliance, Performance and Accounting Systems, IMP's Consultants understand the commercial landscape and have broad, hands-on experience with the world's leading investment software products. To learn more, please visit www.impconsults.com or call (617) 314-7415.


BOSTON, MA, May 15, 2017 (GLOBE NEWSWIRE) -- IMP Consulting, a leader in OMS implementation and compliance solutions for the asset management industry, today announced the release of CLEAR Recon as the latest addition to its growing compliance practice.  The CLEAR (Compliance Library Enhancement and Audit Review) suite of services enable compliance teams to identify and correct inaccurate, duplicate, and outdated rules in the trade OMS compliance rule library for buy-side investment management firms. The latest offering, CLEAR Recon, produces a set of on-demand reports highlighting missing rules, missing accounts or account groups, missing rule assignments, or variances in end-of-day compliance results. CLEAR Recon is a repeatable process that takes the human error component out of compliance reconciliation; reduces the risk of trade errors; and replaces a time-consuming manual process. It can be run at any point in the compliance lifecycle, from rule library analysis to implementation. “Many firms surprisingly rely on Excel spreadsheets for rule reconciliation. One mistake, or even a small typo, in the spreadsheet can have an enormous impact, such as costly trade errors or SEC scrutiny,” said Bryon Williston, Executive Vice President of IMP. “An automated tool, such as CLEAR Recon, takes the human error out of the process, and can deliver the break reports faster, and more accurately.” IMP Consulting, founded in 2004, initially developed CLEAR after observing that many firms were reaching a critical point where the manageability of the compliance rule library, and the process and controls around them, were failing. “CLEAR is backed by a team of compliance experts at IMP who understand the regulatory requirements governing the different investment vehicles, and can accurately translate them into code across all of the market-leading compliance systems,” said Williston. “These specialists work with compliance and IT teams to produce the required import, and properly map the files - saving days, or months of work for people.” The CLEAR suite of services also includes CLEAR 360 and CLEAR On-Demand. Visit http://www.impconsults.com/clear/ for more information. About IMP Consulting IMP Consulting is the industry leader in OMS implementation and compliance solutions for buy-side investment management firms and hedge funds. IMP also offers advisory services, system review and selection, and management of outsourced projects across the front, middle and back-office. Known for their deep subject matter expertise in Trade Order Management, Compliance, Performance and Accounting Systems, IMP's Consultants understand the commercial landscape and have broad, hands-on experience with the world's leading investment software products. To learn more, please visit www.impconsults.com or call (617) 314-7415.


BOSTON, MA, May 15, 2017 (GLOBE NEWSWIRE) -- IMP Consulting, a leader in OMS implementation and compliance solutions for the asset management industry, today announced the release of CLEAR Recon as the latest addition to its growing compliance practice.  The CLEAR (Compliance Library Enhancement and Audit Review) suite of services enable compliance teams to identify and correct inaccurate, duplicate, and outdated rules in the trade OMS compliance rule library for buy-side investment management firms. The latest offering, CLEAR Recon, produces a set of on-demand reports highlighting missing rules, missing accounts or account groups, missing rule assignments, or variances in end-of-day compliance results. CLEAR Recon is a repeatable process that takes the human error component out of compliance reconciliation; reduces the risk of trade errors; and replaces a time-consuming manual process. It can be run at any point in the compliance lifecycle, from rule library analysis to implementation. “Many firms surprisingly rely on Excel spreadsheets for rule reconciliation. One mistake, or even a small typo, in the spreadsheet can have an enormous impact, such as costly trade errors or SEC scrutiny,” said Bryon Williston, Executive Vice President of IMP. “An automated tool, such as CLEAR Recon, takes the human error out of the process, and can deliver the break reports faster, and more accurately.” IMP Consulting, founded in 2004, initially developed CLEAR after observing that many firms were reaching a critical point where the manageability of the compliance rule library, and the process and controls around them, were failing. “CLEAR is backed by a team of compliance experts at IMP who understand the regulatory requirements governing the different investment vehicles, and can accurately translate them into code across all of the market-leading compliance systems,” said Williston. “These specialists work with compliance and IT teams to produce the required import, and properly map the files - saving days, or months of work for people.” The CLEAR suite of services also includes CLEAR 360 and CLEAR On-Demand. Visit http://www.impconsults.com/clear/ for more information. About IMP Consulting IMP Consulting is the industry leader in OMS implementation and compliance solutions for buy-side investment management firms and hedge funds. IMP also offers advisory services, system review and selection, and management of outsourced projects across the front, middle and back-office. Known for their deep subject matter expertise in Trade Order Management, Compliance, Performance and Accounting Systems, IMP's Consultants understand the commercial landscape and have broad, hands-on experience with the world's leading investment software products. To learn more, please visit www.impconsults.com or call (617) 314-7415.


BOSTON, MA, May 15, 2017 (GLOBE NEWSWIRE) -- IMP Consulting, a leader in OMS implementation and compliance solutions for the asset management industry, today announced the release of CLEAR Recon as the latest addition to its growing compliance practice.  The CLEAR (Compliance Library Enhancement and Audit Review) suite of services enable compliance teams to identify and correct inaccurate, duplicate, and outdated rules in the trade OMS compliance rule library for buy-side investment management firms. The latest offering, CLEAR Recon, produces a set of on-demand reports highlighting missing rules, missing accounts or account groups, missing rule assignments, or variances in end-of-day compliance results. CLEAR Recon is a repeatable process that takes the human error component out of compliance reconciliation; reduces the risk of trade errors; and replaces a time-consuming manual process. It can be run at any point in the compliance lifecycle, from rule library analysis to implementation. “Many firms surprisingly rely on Excel spreadsheets for rule reconciliation. One mistake, or even a small typo, in the spreadsheet can have an enormous impact, such as costly trade errors or SEC scrutiny,” said Bryon Williston, Executive Vice President of IMP. “An automated tool, such as CLEAR Recon, takes the human error out of the process, and can deliver the break reports faster, and more accurately.” IMP Consulting, founded in 2004, initially developed CLEAR after observing that many firms were reaching a critical point where the manageability of the compliance rule library, and the process and controls around them, were failing. “CLEAR is backed by a team of compliance experts at IMP who understand the regulatory requirements governing the different investment vehicles, and can accurately translate them into code across all of the market-leading compliance systems,” said Williston. “These specialists work with compliance and IT teams to produce the required import, and properly map the files - saving days, or months of work for people.” The CLEAR suite of services also includes CLEAR 360 and CLEAR On-Demand. Visit http://www.impconsults.com/clear/ for more information. About IMP Consulting IMP Consulting is the industry leader in OMS implementation and compliance solutions for buy-side investment management firms and hedge funds. IMP also offers advisory services, system review and selection, and management of outsourced projects across the front, middle and back-office. Known for their deep subject matter expertise in Trade Order Management, Compliance, Performance and Accounting Systems, IMP's Consultants understand the commercial landscape and have broad, hands-on experience with the world's leading investment software products. To learn more, please visit www.impconsults.com or call (617) 314-7415.


Boston, MA, June 05, 2017 (GLOBE NEWSWIRE) -- IMP Consulting today announced an educational webinar on MiFID II regulation, titled, “MiFID II – US Asset Managers Brace for Impact.” The webinar, featuring Jane Stabile, President of IMP Consulting; Jon Gold, Managing Director of IMP Consulting; and Yanay Lehavi, EVP at PIMCO, will take place on Thursday, June 8, 2017 at 2:00 p.m. ET. The webinar will include a presentation followed by a question-and-answer session. “The original MiFID (Markets in Financial Instruments Directive) impacted UK and European firms, primarily on the sell side. This time around, MiFID II casts a wider net, and has a much greater impact upon the buy side,” said Jane Stabile, President of IMP Consulting. “Many non-EU firms may think that they don’t have to worry, but you may be surprised to learn that your firm is likely to be affected.” This webinar is suited for operations, traders and compliance professionals who are looking for a high-level overview of the key trading requirements, expected impact on order flows, and the implications for US Asset Managers. It will cover four major areas of MiFID II regulation, including: Investor Protection, Best Execution, Trading Transparency, Post-trade Reporting and Unbundling Research. Learn more at www.impconsults.com or Register for the webinar: MiFID II – US Asset Managers Brace for Impact About IMP Consulting IMP Consulting is the industry leader in OMS implementation and compliance solutions for buy-side investment management firms and hedge funds. IMP also offers advisory services, system review and selection, and management of outsourced projects across the front, middle and back-office. Known for their deep subject matter expertise in Trade Order Management, Compliance, Performance and Accounting Systems, IMP's Consultants understand the commercial landscape and have broad, hands-on experience with the world's leading investment software products. To learn more, please visit www.impconsults.com or call (617) 314-7415.


Boston, MA, June 05, 2017 (GLOBE NEWSWIRE) -- IMP Consulting today announced an educational webinar on MiFID II regulation, titled, “MiFID II – US Asset Managers Brace for Impact.” The webinar, featuring Jane Stabile, President of IMP Consulting; Jon Gold, Managing Director of IMP Consulting; and Yanay Lehavi, EVP at PIMCO, will take place on Thursday, June 8, 2017 at 2:00 p.m. ET. The webinar will include a presentation followed by a question-and-answer session. “The original MiFID (Markets in Financial Instruments Directive) impacted UK and European firms, primarily on the sell side. This time around, MiFID II casts a wider net, and has a much greater impact upon the buy side,” said Jane Stabile, President of IMP Consulting. “Many non-EU firms may think that they don’t have to worry, but you may be surprised to learn that your firm is likely to be affected.” This webinar is suited for operations, traders and compliance professionals who are looking for a high-level overview of the key trading requirements, expected impact on order flows, and the implications for US Asset Managers. It will cover four major areas of MiFID II regulation, including: Investor Protection, Best Execution, Trading Transparency, Post-trade Reporting and Unbundling Research. Learn more at www.impconsults.com or Register for the webinar: MiFID II – US Asset Managers Brace for Impact About IMP Consulting IMP Consulting is the industry leader in OMS implementation and compliance solutions for buy-side investment management firms and hedge funds. IMP also offers advisory services, system review and selection, and management of outsourced projects across the front, middle and back-office. Known for their deep subject matter expertise in Trade Order Management, Compliance, Performance and Accounting Systems, IMP's Consultants understand the commercial landscape and have broad, hands-on experience with the world's leading investment software products. To learn more, please visit www.impconsults.com or call (617) 314-7415.


News Article | June 1, 2017
Site: globenewswire.com

SYDNEY, Australia, May 31, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) today announced the formation of a Clinical Advisory Board (CAB) to serve as a strategic resource to the company as it continues to advance the clinical development program and commercialisation path for its lead drug candidate IMP321 for cancer patients worldwide. The CAB will advise Prima on the regulatory and clinical development strategy for its Active Immunotherapy PAClitaxel (AIPAC) clinical trial, which is investigating the safety and efficacy of IMP321 active immunotherapy in combination with paclitaxel chemotherapy in patients with hormone receptor-positive metastatic breast cancer. Dr. Frédéric Triebel, Chief Scientific Officer & Chief Medical Officer of Prima, said: “Securing such a distinguished group of medical professionals is a testament to the growing level of support for immuno-oncology product candidates. While the initial focus of the board will be on developing IMP321 in metastatic breast cancer worldwide, it will also advise us on our other clinical and pre-clinical programs.” The newly formed board will be chaired by Pr. Martine Piccart, who will be joined by Doctor Luc Dirix, Professor David Cameron, Doctor Samson Fung, and Professor Salah-Eddin Al-Batran. Professor Martine J. Piccart is professor of oncology at the Université Libre de Bruxelles (ULB) and Head of the medicine department at the Institute Jules Bordet, in Brussels, Belgium. With a primary interest in breast cancer (BC) and drug development, Prof. Piccart is a leader in international research collaboration and is the co-principal investigator of several large clinical trials, including HERA, MINDACT, and ALTTO. She is co-founder and chair of the Breast International Group (BIG) which unites more than 50 BC research groups around the world. Prof. Piccart is the immediate past president of the European CanCer Organisation (ECCO, 2014-2015). She has also held presidencies of the European Organisation for the Research and Treatment of Cancer (EORTC) and the European Society for Medical Oncology (ESMO), and has served on the American Society of Clinical Oncology Board (ASCO). She joined the Board of Directors of the AACR in 2017. Doctor Luc Dirix is Head of Medical Oncology at the Oncology Center at AZ Sint-Augustinus Hospital in Antwerp, Belgium. He is a member of the American Society for Cancer Research, the European Society of Medical Oncology and the European Organization for Research and Treatment of Cancer. He is past-chairman and current Board member of the Belgian Society of Medical Oncology. Professor David Cameron is the Clinical Director and Chair of Oncology at The University of Edinburgh Cancer Research Centre in the UK. He is a member of the American Society of Clinical Oncology & the European Society for Medical Oncology, and is active in a number of clinical trials in breast cancer in the UK and other countries. Doctor Samson Fung of Fung Consulting in Germany, provides strategic and operational assistance to pharmaceutical and biotech companies including Novartis and Bristol-Myers-Squibb. Dr. Fung is the CEO & Managing Director of Volvox Therapeutics and a member of the American Society of Clinical Oncology, the American Society of Clinical Haematology & the German Society of Pharmaceutical Medicine. Professor Salah-Eddin Al-Batran is the Medical Director at the Institute of Clinical Cancer Research in Frankfurt, Germany. As a haematologist and oncologist, Prof. Al-Batran is on the Board of the University Cancer Centre in Frankfurt, and Task Force director for Phase I/II Trials. He is a member of the German Society of Clinical Oncology, the American Society of Clinical Oncology, and the European Organisation for Research and Treatment of Cancer. About IMP321 IMP321, a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active immunotherapy drugs in which the patient’s own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy. As an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response. Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.


Boston, MA, June 05, 2017 (GLOBE NEWSWIRE) -- IMP Consulting today announced an educational webinar on MiFID II regulation, titled, “MiFID II – US Asset Managers Brace for Impact.” The webinar, featuring Jane Stabile, President of IMP Consulting; Jon Gold, Managing Director of IMP Consulting; and Yanay Lehavi, EVP at PIMCO, will take place on Thursday, June 8, 2017 at 2:00 p.m. ET. The webinar will include a presentation followed by a question-and-answer session. “The original MiFID (Markets in Financial Instruments Directive) impacted UK and European firms, primarily on the sell side. This time around, MiFID II casts a wider net, and has a much greater impact upon the buy side,” said Jane Stabile, President of IMP Consulting. “Many non-EU firms may think that they don’t have to worry, but you may be surprised to learn that your firm is likely to be affected.” This webinar is suited for operations, traders and compliance professionals who are looking for a high-level overview of the key trading requirements, expected impact on order flows, and the implications for US Asset Managers. It will cover four major areas of MiFID II regulation, including: Investor Protection, Best Execution, Trading Transparency, Post-trade Reporting and Unbundling Research. Learn more at www.impconsults.com or Register for the webinar: MiFID II – US Asset Managers Brace for Impact About IMP Consulting IMP Consulting is the industry leader in OMS implementation and compliance solutions for buy-side investment management firms and hedge funds. IMP also offers advisory services, system review and selection, and management of outsourced projects across the front, middle and back-office. Known for their deep subject matter expertise in Trade Order Management, Compliance, Performance and Accounting Systems, IMP's Consultants understand the commercial landscape and have broad, hands-on experience with the world's leading investment software products. To learn more, please visit www.impconsults.com or call (617) 314-7415.


News Article | June 1, 2017
Site: globenewswire.com

SYDNEY, Australia, May 31, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) today announced the formation of a Clinical Advisory Board (CAB) to serve as a strategic resource to the company as it continues to advance the clinical development program and commercialisation path for its lead drug candidate IMP321 for cancer patients worldwide. The CAB will advise Prima on the regulatory and clinical development strategy for its Active Immunotherapy PAClitaxel (AIPAC) clinical trial, which is investigating the safety and efficacy of IMP321 active immunotherapy in combination with paclitaxel chemotherapy in patients with hormone receptor-positive metastatic breast cancer. Dr. Frédéric Triebel, Chief Scientific Officer & Chief Medical Officer of Prima, said: “Securing such a distinguished group of medical professionals is a testament to the growing level of support for immuno-oncology product candidates. While the initial focus of the board will be on developing IMP321 in metastatic breast cancer worldwide, it will also advise us on our other clinical and pre-clinical programs.” The newly formed board will be chaired by Pr. Martine Piccart, who will be joined by Doctor Luc Dirix, Professor David Cameron, Doctor Samson Fung, and Professor Salah-Eddin Al-Batran. Professor Martine J. Piccart is professor of oncology at the Université Libre de Bruxelles (ULB) and Head of the medicine department at the Institute Jules Bordet, in Brussels, Belgium. With a primary interest in breast cancer (BC) and drug development, Prof. Piccart is a leader in international research collaboration and is the co-principal investigator of several large clinical trials, including HERA, MINDACT, and ALTTO. She is co-founder and chair of the Breast International Group (BIG) which unites more than 50 BC research groups around the world. Prof. Piccart is the immediate past president of the European CanCer Organisation (ECCO, 2014-2015). She has also held presidencies of the European Organisation for the Research and Treatment of Cancer (EORTC) and the European Society for Medical Oncology (ESMO), and has served on the American Society of Clinical Oncology Board (ASCO). She joined the Board of Directors of the AACR in 2017. Doctor Luc Dirix is Head of Medical Oncology at the Oncology Center at AZ Sint-Augustinus Hospital in Antwerp, Belgium. He is a member of the American Society for Cancer Research, the European Society of Medical Oncology and the European Organization for Research and Treatment of Cancer. He is past-chairman and current Board member of the Belgian Society of Medical Oncology. Professor David Cameron is the Clinical Director and Chair of Oncology at The University of Edinburgh Cancer Research Centre in the UK. He is a member of the American Society of Clinical Oncology & the European Society for Medical Oncology, and is active in a number of clinical trials in breast cancer in the UK and other countries. Doctor Samson Fung of Fung Consulting in Germany, provides strategic and operational assistance to pharmaceutical and biotech companies including Novartis and Bristol-Myers-Squibb. Dr. Fung is the CEO & Managing Director of Volvox Therapeutics and a member of the American Society of Clinical Oncology, the American Society of Clinical Haematology & the German Society of Pharmaceutical Medicine. Professor Salah-Eddin Al-Batran is the Medical Director at the Institute of Clinical Cancer Research in Frankfurt, Germany. As a haematologist and oncologist, Prof. Al-Batran is on the Board of the University Cancer Centre in Frankfurt, and Task Force director for Phase I/II Trials. He is a member of the German Society of Clinical Oncology, the American Society of Clinical Oncology, and the European Organisation for Research and Treatment of Cancer. About IMP321 IMP321, a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active immunotherapy drugs in which the patient’s own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy. As an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response. Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.


News Article | December 21, 2016
Site: www.marketwired.com

SYDNEY, AUSTRALIA--(Marketwired - Dec 21, 2016) - Prima BioMed Ltd ( : PRR) ( : PBMD) ("Prima" or the "Company") today announced interim data from the AIPAC Phase IIb clinical trial for IMP321 in metastatic breast cancer (Active Immunotherapy PAClitaxel). The initial data confirms previous trial results showing IMP321 is safe and well tolerated. In this Phase IIb study of IMP321 plus paclitaxel chemotherapy in patients with hormone receptor-positive metastatic breast cancer, data from all 15 patients in the safety run-in phase demonstrated that IMP321 is safe and well tolerated at both the 6mg and 30mg dosage levels. Immune monitoring data has also confirmed that IMP321, as an Antigen Presenting Cell (APC) activator, is working to generate the desired immune responses. The data demonstrated activation and an increased level of blood monocytes, dendritic cells and CD8 T-cells. Prima's Chief Medical Officer, Dr Frédéric Triebel, said: "Following the initial data released in June, we are now very pleased to confirm the safety, pharmacokinetics and pharmacodynamics of IMP321 across the initial patient cohorts at both dosage levels. This is another important step in de-risking our AIPAC trial as we look to commence the enlarged randomised and double-blind phase in the new year. We also look forward to providing further insights into efficacy of these safety run in patients by the middle of 2017." Subject to the confirmation of the dose escalation committee on the 30th December, Prima will now commence the randomised phase of the trial in January 2017. Patients will receive paclitaxel treatment plus placebo or paclitaxel in conjunction with IMP321. IMP321 is a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3. IMP321 represents one of the first proposed active immunotherapy drugs in which the patient's own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy. As an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response. IMP321 has been shown in an open-label Phase I study1, to be able to double the expected six-month response rate in HER-2 negative metastatic breast cancer patients receiving standard-of-care paclitaxel; from a 25% historic response rate2, to 50% when combined with IMP321. Prima BioMed is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. Prima's current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. IMP321, which is a soluble LAG-3Ig fusion protein, is an APC activator boosting T cell responses. IMP321 is currently in a Phase II clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT 02614833) and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT 02676869). A number of additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners. Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.

Loading imp Inc collaborators
Loading imp Inc collaborators